Achieve Life Sciences (NASDAQ:ACHV) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of Achieve Life Sciences (NASDAQ:ACHV) from a sell rating to a hold rating in a research report released on Sunday.

Several other equities analysts have also recently commented on ACHV. Weiss Ratings cut Achieve Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 8th. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Achieve Life Sciences in a report on Thursday, April 16th. Finally, Canaccord Genuity Group set a $13.00 price objective on shares of Achieve Life Sciences and gave the company a “buy” rating in a research note on Monday, April 20th. Two research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Achieve Life Sciences has an average rating of “Buy” and a consensus price target of $14.67.

Achieve Life Sciences Price Performance

ACHV stock opened at $5.29 on Friday. Achieve Life Sciences has a twelve month low of $2.00 and a twelve month high of $6.15. The company has a quick ratio of 2.62, a current ratio of 2.62 and a debt-to-equity ratio of 0.87. The company has a market cap of $281.59 million, a PE ratio of -4.72 and a beta of 2.25. The business’s 50-day simple moving average is $4.07 and its 200 day simple moving average is $4.47.

Achieve Life Sciences (NASDAQ:ACHV) last posted its quarterly earnings results on Tuesday, May 12th. The biopharmaceutical company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.11. On average, research analysts anticipate that Achieve Life Sciences will post -0.91 earnings per share for the current year.

Hedge Funds Weigh In On Achieve Life Sciences

A number of hedge funds have recently made changes to their positions in ACHV. Franklin Resources Inc. raised its stake in shares of Achieve Life Sciences by 18,747.4% in the 4th quarter. Franklin Resources Inc. now owns 4,369,193 shares of the biopharmaceutical company’s stock valued at $21,715,000 after buying an additional 4,346,011 shares in the last quarter. Hudson Bay Capital Management LP acquired a new position in shares of Achieve Life Sciences in the 2nd quarter valued at $2,652,000. Millennium Management LLC raised its stake in shares of Achieve Life Sciences by 472.3% in the 4th quarter. Millennium Management LLC now owns 1,359,116 shares of the biopharmaceutical company’s stock valued at $6,755,000 after buying an additional 1,121,614 shares in the last quarter. Pathstone Holdings LLC acquired a new position in shares of Achieve Life Sciences in the 3rd quarter valued at $1,581,000. Finally, KVP Capital Advisors LP acquired a new position in shares of Achieve Life Sciences in the 4th quarter valued at $2,298,000. Institutional investors and hedge funds own 33.52% of the company’s stock.

Key Headlines Impacting Achieve Life Sciences

Here are the key news stories impacting Achieve Life Sciences this week:

• Positive Sentiment: HC Wainwright raised its FY2026, FY2027 and some interim earnings estimates for Achieve Life Sciences and kept a Buy rating with a $12 price target, signaling continued long-term optimism. HC Wainwright analyst update
• Positive Sentiment: Zacks Research also lifted its forecasts, including a higher FY2027 EPS estimate and a positive long-term view with FY2028 EPS turning profitable, which may support sentiment around Achieve’s future earnings power. Zacks Research estimate update
• Neutral Sentiment: The company’s latest reported quarterly results beat expectations, which remains a supportive backdrop, but the stock’s recent move appears driven more by analyst revisions than fresh operating news. Earnings results reference
• Negative Sentiment: A Seeking Alpha note titled “Hold” On Expected CRL Cytisinicline And Q4 2026 NDA Resubmission points to regulatory risk and a possible delay in the company’s pathway for cytisinicline, likely weighing on the shares. Seeking Alpha article
• Negative Sentiment: Another report said Achieve Life Sciences’ price target was cut by 14.04% to $12.82, reinforcing concerns that investors are becoming more cautious about near-term catalysts. Price target cut article

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.